258 related articles for article (PubMed ID: 22179855)
1. Cooperation between Polycomb and androgen receptor during oncogenic transformation.
Zhao JC; Yu J; Runkle C; Wu L; Hu M; Wu D; Liu JS; Wang Q; Qin ZS; Yu J
Genome Res; 2012 Feb; 22(2):322-31. PubMed ID: 22179855
[TBL] [Abstract][Full Text] [Related]
2. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
3. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
4. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
5. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.
Wu L; Runkle C; Jin HJ; Yu J; Li J; Yang X; Kuzel T; Lee C; Yu J
Oncogene; 2014 Jan; 33(4):504-13. PubMed ID: 23318417
[TBL] [Abstract][Full Text] [Related]
6. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
[TBL] [Abstract][Full Text] [Related]
7. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
8. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
9. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
[TBL] [Abstract][Full Text] [Related]
10. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Yu J; Yu J; Mani RS; Cao Q; Brenner CJ; Cao X; Wang X; Wu L; Li J; Hu M; Gong Y; Cheng H; Laxman B; Vellaichamy A; Shankar S; Li Y; Dhanasekaran SM; Morey R; Barrette T; Lonigro RJ; Tomlins SA; Varambally S; Qin ZS; Chinnaiyan AM
Cancer Cell; 2010 May; 17(5):443-54. PubMed ID: 20478527
[TBL] [Abstract][Full Text] [Related]
11. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
12. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
[TBL] [Abstract][Full Text] [Related]
13. PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors.
Videira A; Beckedorff FC; daSilva LF; Verjovski-Almeida S
Cell Commun Signal; 2021 Jan; 19(1):5. PubMed ID: 33430890
[TBL] [Abstract][Full Text] [Related]
14. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
15. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
16. BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation.
Lempiäinen JK; Manjur ABMK; Malinen M; Ketola K; Niskanen EA; Palvimo JJ
Oncogene; 2020 Mar; 39(11):2391-2407. PubMed ID: 31925334
[TBL] [Abstract][Full Text] [Related]
17. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
20. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]